Current treatment of Cutaneous T-Cell Lymphoma

Dermatol Online J. 2001 Feb;7(1):3.

Abstract

Cutaneous T-cell lymphomas are a heterogeneous group of cutaneous non-Hodgkin's lymphomas. In the United States, the incidence of these diseases is rising faster than any other cancer. Environmental triggers may be important in the evolution of malignancy. Current therapy is reviewed with emphasis on a new retinoid, Targretin.

Publication types

  • Review

MeSH terms

  • Administration, Oral
  • Administration, Topical
  • Anticarcinogenic Agents / therapeutic use*
  • Apoptosis / drug effects
  • Bexarotene
  • Biopsy
  • Carmustine / administration & dosage
  • Disease Progression
  • Drug Eruptions / etiology
  • Humans
  • Hypertriglyceridemia / chemically induced
  • Lymphoma, T-Cell, Cutaneous / drug therapy*
  • Lymphoma, T-Cell, Cutaneous / pathology
  • Mechlorethamine / administration & dosage
  • Mechlorethamine / adverse effects
  • Neoplasm Staging
  • PUVA Therapy
  • Prognosis
  • Retinoids / therapeutic use
  • Sezary Syndrome / drug therapy
  • Sezary Syndrome / immunology
  • Tetrahydronaphthalenes / adverse effects
  • Tetrahydronaphthalenes / therapeutic use*
  • Vitamin D / therapeutic use

Substances

  • Anticarcinogenic Agents
  • Retinoids
  • Tetrahydronaphthalenes
  • Vitamin D
  • Mechlorethamine
  • Bexarotene
  • Carmustine